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Effects of Ozone on Blood Components 
 
 
Daniela Sloan 
 
 
ABSTRACT 
 
 
 Previous studies on the medical use of ozone therapies show a very diverse array 
of results, from ozone reducing the amount of HIV virus in the blood, to no effect, to 
causing the death of several patients due to pulmonary embolism and infections. 
However, ozone therapies are widely used in Europe and considered medically safe. In 
the U.S., doctors in 28 states use ozone therapies. 
The objectives of this study were to investigate the effects of medical grade ozone 
at varying concentrations used in ozone therapies. These were achieved by evaluating the 
C-reactive protein, erythrocyte sedimentation rate, total reduced and oxidized glutathione 
content of erythrocytes which were all markers used to determine ozone 
injury/inflammation. 
Despite the fact that ozone is a very strong oxidant, previous research indicates 
that depending on the dose and the health status of the biological system, sometimes 
ozone can act as an antioxidant. 
 The medical exposure range for ozone is between 20 -80 µg/ml with an average 
of 50 µg/ml. The concentrations used in this study were 20, 40, 80 and 160 µg/ml. 
 ii 
Ozone was generated in the “Breath Lab” at USF from medical grade oxygen obtained 
through electrical corona arc discharge using an OL80C ozone generator. De-identified 
blood samples of 10 ml blood/sample containing EDTA as anticoagulant were obtained 
from the James A. Haley VA Hospital patients. Equal volumes of blood and ozone gas 
mixture were allowed to mix in ozone-resistant syringes prior to dividing each sample 
into three parts, one for each corresponding parameter to be studied. The C-reactive 
protein was analyzed through ELISA using the colorimetric method available from 
Helica Biosystems; erythrocyte sedimentation rate was measured in graduated 
sedimentation tubes; the total reduced glutathione (GSH) and oxidized glutathione 
(GSSG) content of erythrocytes was determined according to the colorimetric method 
developed by the Oxford Biomedical Research. 
 Overall, the concentrations of ozone used did not have a statistically significant 
effect on the parameters investigated. However, a small percentage of the blood samples 
showed an improvement in the parameters studied, especially at the highest ozone 
concentration. 
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Introduction 
 
 
Background 
 
 
Ozone is one of the five major air pollutants along with carbon monoxide, sulfur 
dioxide, nitrogen dioxide and particulates. The difference between ozone and these four 
pollutants is the fact that it is not emitted directly into the air from industrial facilities, 
power plants or automobiles. Instead, ozone is a photochemical pollutant, a major 
component of photochemical smog, created when the sunlight mediates chemical 
reactions with other pollutants (Breslin, 1995). Due to this effect, human exposures to 
atmospheric ozone are of interest and thus have been studied for a long time. Most 
commonly the effects of ozone are lung injury, respiratory infections and inflammation 
caused by ozone concentrations of 0.1 ppm in adults and as little as 0.085 ppm in 
children. These findings prompted the USEPA to revise its 0.12 ppm standard and set a 
limit of 0.08 ppm ozone/8 hours, based on the decision that this level protects the public 
health (Moore 1999). However, studies on southern Californians showed that the 
pulmonary function changes at 0.5 ppm are less severe during a high-ozone season 
compared to a low-ozone season, suggesting an increased tolerance to ozone but not less 
cellular damage (Munzer et al., 1995). On the other hand, ozone has been widely used in 
the medical field for ozone therapies, the most common being ozone autohemotherapy or 
ozonated autohemoadministration (Hiromichi et al. 2006, 
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en.wikipedia.org/wiki/Ozone_therapy). Autohemotherapy is an alternative medical 
technique practiced for about 50 years in Europe, which involves withdrawing up to 200 
ml of venous blood, then immediately mixing it with therapeutic concentrations of ozone 
gas and a minimal amount of anticoagulant, usually heparin, then re-injecting it into the 
basilic vein at the elbow. Other techniques are ozone bagging, when all parts of the body 
except for the head are placed in a bag full of ozone at a concentration of 100 µg of ozone 
/ml air mixture for up to 2 hours; ozone rectal insufflation, where an average of about 1 
1/2 liters of 27 µg/ml O3 gas are introduced into the colon; ozone vaginal insufflation, 
where the vagina is insufflated for about 5 minutes; ozone ear insufflation, where O3 is 
introduced in the ear cavity for an average of 5 minutes; ozone air purification, where low 
levels of ozone sterilize and rejuvenate the room air and lastly ozone charged drinking 
water,  where O3 is bubbled into water which must be imbibed immediately while the O3 
is still in the glass (oxygenmedicine.com). Experimental evidence suggests that these 
therapies may boost the immune system, reduce the number of viruses in the blood and a 
reduction in lung, breast and uterine tumors (Sweet et al. 1980). A study by Wells et al. 
(1991) demonstrated that ozone was able to inactivate HIV-1 virions in a dose- dependent 
manner. Ozone concentrations of 1200 ppm achieved greater than 11-log virus 
inactivation within 2 hours from ozone administration (2-log means 99% inactivation). 
The authors developed and used a T cell line – HUT 78/HIV-1AAV stably infected with 
HIV-1. The ozone was delivered into the cell medium through a closed hollow fiber 
system as a stream of ozone/oxygen, using nitrogen as the carrier.  
     Ozone therapy is used legally in 16 countries, mostly in Europe. In the U.S., recently 
passed Alternative Therapy Legislation has made ozone therapy an option for patients in 
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13 states. In Alaska, Arizona, Colorado, Georgia, Minnesota, New York, New Jersey, 
North Carolina, Ohio, Oklahoma, Oregon, South Carolina, and Washington, physicians 
can legally use ozone treatments in their practice without fear of prosecution. 
(wikipedia.org). 
 Scientific papers that described studies on the effects of ozone and/or ozone 
therapies in relation to blood provided contradicting results. First, there are the studies 
that found no effect of ozone on blood and blood constituents. Biedunkiewicz et al. 
(2006) found no evidence that ozone affects blood coagulation and fibrinolysis. It would 
have been expected that ozone reduces blood viscosity and inhibits coagulation, which 
are important side effects for patients undergoing hemodialysis.  Autohemoadministration 
lead to no statistical differences between C-reactive protein at baseline and after ozone 
treatment in patients undergoing hemodialysis (Tylicki et al. 2004). This result proved 
that autohemoadministration is safe for the patients. Zimran et al. (1999) showed that 
ozone does not affect red blood cell enzymes and intermediates or red blood cell 
integrity. Furthermore, ozone neither damage erythrocytes, nor induced oxidation of 
intracellular hemoglobin in the case of heparin-treated blood (wikipedia.org). A study by 
Travagli et al. (2006) did not yield significant hemolysis or methemoglobin when whole 
blood was treated with a therapeutic concentration of ozone. In contrast, there are studies 
that showed either a negative or a positive effect of ozone. Bocci et al. (1999) showed 
that during ozonated autohemotherapy, ozone induced formation of platelet aggregation 
(blood clots) in heparin (anticoagulant)-treated blood (Bocci et al. 1996). Larini and 
Bocci (2004) showed that cytokine production was depressed at ozone concentrations 
above 40 µg/ml. Bocci (2006) advocated the use of ozone therapies and ending the 
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labeling of ozone therapies as a dangerous or toxic, while recognizing that atmospheric 
ozone can be responsible for respiratory system damage. In this case, ozone therapies 
were shown to improve blood circulation and oxygen delivery to ischemic tissues and 
induce a mild activation of the immune system (Bocci 2006). The same author, Bocci 
(2007) later demonstrated that ozone can activate biochemical pathways in leukocytes, 
erythrocytes and platelets without acute or chronic toxicity, and decreases blood plasma 
antioxidant capacity for about 20 minutes (Bocci, 2007). Patients under maintenance 
hemodialysis who were given autohemoadministration showed a decrease in blood access 
recirculation, which is the return of the dialyzed blood into the extracorporeal circuit 
through the arterial needle, rather than returning to the systemic circulation. This is a 
positive effect, helping to maintain the effectiveness of hemodialysis, even though these 
results were not statistically significant (Tylicki et al. 2004). 
Blomberg et al. (2003) showed that exposure to atmospheric ozone impairs lung 
function, induces airway inflammation and alters epithelial permeability, as shown by 
analysis of CC16 protein from peripheral blood (Blomberg et al. 2003). Animal studies 
showed that ozone exposure results in local bronchial inflammation and also affects the 
nervous system and thymocyte proliferation, and places mice under oxidative stress 
(Feng et al. 2006). In rats, ozone exposed animals had an increased lyzozyme activity and 
a decreased total protein, both being an indicator of liver disease (Jakubowski et al. 
2004). Another study on mice by Kenyon et al. (2006) demonstrated that ozone induced 
acute lung injury but the NOS2 enzyme present in some mice had a protective effect 
against lung injury. Experiments on male rats resulted in a positive linear relationship 
between ozone concentration and the concentrations of serum total lipoprotein free 
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cholesterol (FCh) and high-density lipoprotein total cholesterol (HDL-Ch) (Mole et al. 
1985). A study reported by Hiromochi et al. (2006) on the effects of ozone 
autohemoadministration in cows, showed significant changes in leukocyte populations 
following ozone blood stimulation (Hiromichi et al. 2006). Other studies showed were 
that exposure to ozone increases sensitivity to the toxicity of other chemicals like 1-
nitronaphtalene (Schmelzer et al. 2006); external ozone exposure combined with internal 
exposure to PAHs and VOCs resulted in low level of DNA damage in teenagers but it is 
not clear if ozone alone can be responsible for the mutations (Koppen et al. 2007). Air 
pollutants, including ozone, were shown to cause pulmonary inflammation in both human 
and animals under experimental conditions; this causes an increase in the liver 
inflammatory markers, fibrinogen and C-reactive protein. However, when air pollutant 
exposure of 40 healthy volunteers was studied over the course of a 1-year period, there 
was no relationship between air pollutants and the amount of fibrinogen and CRP (Rudez 
et al. 2009). Lab experiments on healthy volunteers showed that exposure to an ambient 
air ozone concentration of 0.5 ppm induced a significant decrease in vital capacity and 
total lung capacity, expiratory flow rates and an increase of respiratory frequency on 
exercise (Hazucha et al. 1989).This concurs with a study by Bowler and Crapo (2002) 
showing that ozone exposure decreases the forced expiratory volume FEV1 and children 
playing in areas with high concentrations of environmental ozone have a higher incidence 
of asthma. Despite these results, a review of 24 studies concluded that a threshold 
concentration below which no effects on pulmonary function are elicited cannot be 
defined (Hazucha, 1987). 
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 A positive effect of ambient ozone was noticed when cancer cells extracted from 
lung, breast and uterine tumors were exposed to ozone concentrations between 0.3 to 0.8 
ppm in ambient air. Concentrations between 0.3 to 0.5 ppm inhibited cancer growth 
between 40 and 60 percent. A concentration of 0.8 ppm inhibited cancer cell growth more 
than 90 percent. This shows that human cancer cells have an impaired defense 
mechanism against ozone, compared to normal cells (Sweet et al. 1980). 
A summary of some of the previous studies on ozone therapies and their effects, 
positive, negative or no effect is given below in Table 1. 
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Table 1. Summary of Previous Studies on Ozone. 
 
  
 
Previous studies Sample 
size 
Positive effects Negative effects No effect 
Guven et al.  (2009) rats Reduced intestinal damage, oxidative stress 
  
Rodriguez et al. (2009)  rats Increase in antioxidant enzymes, decrease 
myeloperoxidase (damage marker) in lungs 
  
Labuschagne et al 
(2009) baboons Up-regulated antioxidant capacity 
  
Schultz et al. (2008) rabbits Remission of squamous cell carcinoma   
Jiao & Peng (2008) 42 Improvement in liver function for hep. B   
Mustafaev et al. (2007) 20 
Prevention of pyoinflammatory complications  
following transurethral resection of prostatic 
adenoma 
  
Ohtsuka et al. (2006) cows Increased CD4+/CD8+ ratio   
Jakubowski et al. (2004) rats Increased lysozyme activity, decreased total protein level 
  
Clavo et al. (2004) 18 Improved oxygenation in hypoxic tumors   
Simonetti et al. (2003) 600 Additive effect for lumbar disk herniation   
Al-Dalain et al (2001) rats Improvement in glycemic control   
Sweet et al. (1980) cells Inhibited cancer cell growth 
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Table 1 (Continued) 
 
 
 
 
 
 
 
Blomberg et al. (2003) 22  Increased CC16 serum (marker for ozone-induced lung damage)  
Hazucha et al. (1989) 14  Inhibited inspiration, reduced total lung capacity 
and vital capacity  
Forsberg et al.  3430  Increased blood fibrinogen  
Gornicki & Gutse 
(2000) cells  
Lead to changes in erythrocyte membranes, 
cytoskeletal proteins  
     
Schmelzer et al. 
(2006) rats   On cytokine production 
Biedunkiewicz et al. 
(2006) 11   
On blood coagulation 
parameters 
Tylicki et al. (2004) 12   
On inflammation  
response in 
 hemodialyzed patients 
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 The main difference between the studies that did not find any effects of ozone on 
blood and the studies that found a wide diversity of effects, can be attributed to the 
different methodology used. In general, the findings of the studies with no effects were 
based on  a single concentration of ozone to work with; whereas the studies that were 
able to prove that ozone had either a positive or negative effect looked at several ozone 
concentrations. However, the latter analyzed a specific problem such as heparinized 
blood from male donors (wikipedia.org), heparinized or citric acid treated blood from 
volunteers between 23 and 27 years old, plasma (Bocci et al. 1999), release of cytokines 
from mononuclear cells (Larini & Bocci 2005), total cholesterol in male rats (Mole et al. 
1985) or methemoglobin (Bocci & Aldinucci 2006). Another possible explanation for the 
in vitro damaging effect of ozone on blood components is that the ozone toxicity is 
exerted when cells are incubated in anti- oxidant-free culture media and therefore do not 
benefit of the antioxidant capacity of the blood (Larini & Bocci, 2005). 
 According to Hernandez (2007), one of the reasons why ozone in medicine has not 
been approved as a common practice is its use without an appropriate control. The main 
ozone therapy mechanism of action is based on an extremely transitory and regulated 
oxidative stress imposed ex vivo (Bocci, 2002). At the same time, ozone therapy acts as 
an efficient oxidative stress regulator stimulating the antioxidant system of the cell. As 
reactive oxygen species attack a variety of organic substrates, oxidative stress can be 
evaluated by measuring reaction products of oxidative damage. Because of this, it would 
be necessary to assess the patient's redox status before and during application of ozone 
therapy in order to control the safety doses of ozone to be applied in each application.  
 Previous reports remarked on the lack of studies on the effects of ozone on the 
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immune responses, on peripheral blood leukocytes, the mechanism of ozone therapies 
and that there are controversies on whether the blood should be diluted or not. 
Furthermore, while the fact that ozone damages the membrane of erythrocytes is well 
known, the ozone therapies are considered by many as safe but others claim that ozone 
concentrations within the medical range cause degradation of the proteins in erythrocyte 
membranes (Fischbach, 2000).  
 Common markers of inflammatory responses to infections and chemical agents are 
an increase in C- reactive protein and a short-term increase in GSH (glutathione) levels. 
Glutathione is an antioxidant that protects cells from toxins such as free radicals 
generated by the powerful oxidative properties of ozone. The C-reactive protein is 
usually absent in the blood of healthy persons and appears rapidly in blood and body 
fluids as a response to injurious stimuli (Fischbach, 2000). However, another study by 
Ridker et al. (2000) showed that high levels of the high sensitivity C-reactive protein 
were found in the blood of healthy postmenopausal women. Later on, these women 
developed various forms of cardiovascular disease and hsCRP was the significant 
predictor of cardiovascular risk out of 12 plasma variables. This result confirmed a 
previous study (Kuller et al., 1996) which was the first to show a direct correlation 
between CRP and coronary heart disease (CHD) mortality in healthy but high risk men. 
The correlation between CRP and CHD mortality is strengthened when other risk factors 
like smoking are present. However, the results of this study were not able to show a 
correlation between CRP and nonfatal myocardial infarctions, only a correlation between 
CRP and CHD deaths. Ridker et al. (2005) pursued this topic and for high sensitivity 
assays of CRP, their cut-offs were less than 1 mg/L for low risk, 1 to 3 mg/L for 
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moderate risk, and greater than 3 mg/L for high risk. The drawback is that the continuum 
extends beyond that. The patients with the very highest levels of hsCRP —5 to 10, 10 to 
20, or even greater than 20 mg/L—are at the very highest risk. These were not false 
positives and they helped to explain why people with periodontal disease, arthritis, and 
other systemic inflammatory disorders had higher vascular risk. A plausible explanation 
is that inflammation from any cause has an adverse effect on the vascular endothelium.  
 Antioxidant enzymes like copper/zinc superoxide dismutase (SOD), catalase and 
gluthatione peroxidase (GSHPx) are part of the intracellular protection mechanism 
important in  overcoming oxidative stress and are known to be activated in vascular 
diseases and acute stroke (Zimmermann et al. 2004). In this study, nearly two thirds of 
the patients with a stroke in the past showed decreased GSH levels and the authors 
speculate it was possibly associated with increased oxidative stress and arteriosclerosis. 
The GSH levels and antioxidant capacity are also decreased following an organ 
transplant, which may indicate the need for glutathione supplementation to improve 
antioxidant status (Wierzbicka et al. 2007). Glutathione (GSH) is an important tripeptide 
thiol (γ-glutamyl cysteinyl glycine) antioxidant and its intracellular concentration is 
indicative of oxidative stress. The oxidative stress is a common marker of many diseases 
such as chronic lung diseases, neurodegenerative diseases rheumatoid arthritis, 
amyotrophic lateral sclerosis and most recently AIDS (Rahman et al. 2005, Halliwell 
1996). Within the cell glutathione is found in two forms: GSH, the reduced sulfhydryl 
form and GSSG, the oxidized disulfide form (Rahman et al. 2005). A summary of some 
of the previous studies on ozone therapies and their effect on blood is given below in 
Table 2.  
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Table 2. Summary of Previous Studies on Blood and Ozone. 
EFFECTS OF OZONE ON FINDINGS FROM 
PREVIOUS STUDIES 
SAMPLE 
SIZE ESR CRP GSH OTHER 
Bocci et al. 2006 1 n/a n/a n/a Total antioxidant status decreased temporarily 
Travagli et al. 2007 3 No effect  
Decrease in GSH 
enzymes but not 
significant 
Decrease in total antioxidant status, no 
effect on fibrinogen, cholesterol 
Bocci et al. 1999 5   No effect Decrease in total antioxidant status, 
reversible platelet aggregation 
Biedunkiewicz et al. 
2006 11    
No effect on blood coagulation, 
fibrinolysis 
Tylicki et al. 2004 12  No effect   
Gornicki & Gutsz, 2000 21?    Effect on erythrocyte membrane fluidity is dose dependent 
Clavo et al. 2004 18    Ozone increased tumor oxygenation 
Goran et al. 2009 40  No effect  Ozone increased platelet aggregation, thrombin generation 
Mustafaev et al. 2007 20 Decrease   Increase in leukocytes, phagocytes 
Haddad et al. 2009 horses    
Decrease in gamma 
glutamyltransferase, increase in 
fibrinogen 
Ohtsuka et al.2005 cows    Increase in plasma protein, serum protein, α and γ globulin, CD4+T cells 
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Table 2 (Continued) 
 
 
 
 
 
 
Lambuschagne et al. 2009 baboons   Decrease in total GSH  
Rodriguez et al. 2009 
-O2/O3 mix insufflated in to 
lower abdomen, not blood 
rats   Increase in GSH enzyme 
activity  
Guven et al. 2009 rats   Increase in GSH enzyme 
activity  
Al-Dalain et al. 2001 rats    Ozone prevented oxidative stress damage 
                                                                              INHALED OZONE  
Forsberg et al -poster 3430    Ozone increases the amount of fibrinogen 
Blomberg et al. 2003 22    Ozone increased serum Clara cell protein 
Jakubowski et al. 2004 rats  Decreased levels   
 
Rudez et al. 2009 40  No effect    
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During the past couple of decades, ozone has been wildly used in the medical 
field as ozone therapies, the most common being ozone autohemotherapy or ozonated 
autohemoadministration. However, its effects are still controversial. Advocates of these 
techniques sustain that ozone is beneficial for treating a large array of diseases including 
inflammatory and degenerative conditions of the bones and joints, cardiovascular 
diseases, reducing viral load in HIV infections and stopping cancer proliferation.  At the 
other end of the spectrum, there are ozone treatments that resulted in the death of the 
patients or infections. The early techniques of injecting ozone gas into the patients veins, 
lead to pulmonary embolism and death of the patients. Most recently, the only fatality 
was caused by septicemia as a result of using contaminated needles and a more frequent 
effect was infection with hepatitis virus; however, these are not a consequence of ozone 
exposure, they are a result of improper administration of medical techniques. 
It is common knowledge that ozone is a very strong oxidant, with a solubility 10-
times higher than oxygen. Therefore, it would be expected that ozone would cause cell 
membrane damage, oxidative stress and inflammation. The reasons why it is so hard to 
assign ozone therapies to a definite class of effects can be explained by the “poison 
paradox: chemicals can behave as friends or foes depending on the dose and the 
biological system”. Taking it a step further, it is known that “most drugs produce many 
effects, all drugs produce at least two effects (Walsh, 2005). In conclusion, even though 
ozone is a strong oxidant, sometimes it can act as an antioxidant. 
The objectives of this study are to improve the study design, used previously by other 
researchers, to determine optimal sample size and ozone concentration interval, to evaluate a 
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combination of inflammation and oxidative stress markers and to provide an answer to the 
controversy over the effects of ozone therapies. 
The primary hypotheses tested were:  
 
1. The concentration of C-reactive protein in the blood does not increase with 
increasing concentrations of ozone in blood. 
2. Erythrocyte sedimentation rate is not affected by increasing concentrations of 
ozone in blood. 
3. The ratio of reduced/oxidized glutathione does not change with increasing 
concentrations of ozone in blood. 
 
The secondary hypotheses tested were: 
 
       1a. Ozone concentrations above 100 µg of ozone/ml of blood will increase the 
concentration of C- reactive protein in blood. 
       2a. Erythrocyte sedimentation rate increases with increasing concentrations of 
ozone in blood. 
       3a. The amount of oxidized glutathione increases with increasing concentrations of 
ozone in blood. 
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Significance of the research 
 
 
This study does not approve or disapprove of the use of ozone therapies, but it does  
intend to shed some light onto the controversy that surrounds the health effects of ozone. 
The purpose of the study is to look at the effects of varying ozone concentrations that are 
within medical range (50-100 µg ozone/ml blood) compared to untreated blood, and the 
effects of ozone concentrations up to 3 times higher than the most common blood ozone 
therapy concentration, 50 µg ozone/ml blood and detect the concentration where ozone 
starts to have a deleterious effect on blood components that are primary markers of injury 
and/or inflammation. Previous studies analyzed different parameter combinations than 
the ones chosen in this study, and generally used only one ozone concentration and had a 
very small sample size consisting of patients with little variation in their health status. In 
general, autohemotherapy uses a concentration of 50 µg ozone /ml blood. Bagging 
techniques use higher concentrations, usually 100 µg ozone /ml air mixture.  
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Methods 
 
 
Blood sample collection and preparation 
 
 
The experiments were conducted on de-identified blood samples collected from 
the James A. Haley VA Hospital patients who were scheduled to have blood drawn by 
the Phlebotomy Lab staff. The sample size was set to include 20 patients and the blood 
from each patient was split into five subsamples, one to serve as a control and the other 
four to be treated with various ozone concentrations. The tests chosen to assess ozone 
damage were erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and 
glutathione ratio (GSH/GSSG). According to the study protocols used, the amounts of 
blood needed for each subsample were 1 ml blood for ESR, 150 µl blood for GSH/GSSG 
and 850 µl blood for CRP for a total of 2 ml/subsample and a total of 10 ml for a full set 
of experiments for each patient. Initially, the study design required each patient to donate 
30 ml of blood, aside from the blood needed for the VA Hospital tests, in order to provide 
three replicates for each test. Following consultations with the VA Hospital and the IRB 
committee, it was decided that each patient will donate 10 ml of blood for this study. All 
patients who agreed to take part in this study were given information about the study, 
asked to acknowledge if they meet the exclusion criteria and then asked to sign a consent 
form. Because the parameters studied can be affected by certain inflammatory conditions, 
the exclusion criteria for the study were patients with HIV, hepatitis, rheumatoid arthritis, 
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pneumococcal meningitis, chronic lung disease, congestive heart failure, sickle cell 
anemia, polycythemia, inflammatory bowel disease and post-transplant patients. The 
blood was collected in tubes coated with EDTA to prevent blood coagulation.  
Due to a high concern for the privacy of the patients it was not possible to 
persuade the IRB committee that a label of random sequences of numbers and letters 
would be de-identified enough to protect the privacy of the patients. As a result, in order 
to have to tubes labeled with random and unrelated codes, astronomical data for sun 
rising and setting as provided by the U.S. Navy Oceanography portal for different cities 
in the U.S. was used. None of these cities or data were associated with Tampa, FL or the 
James A. Haley VA Hospital. Once the blood was collected, the tubes were placed on ice 
and transported to the “Breath Lab” in the College of Public Health where the 
experiments were conducted. The ozone was produced by an ozone generator, using 
medical-grade oxygen. The ozone concentrations used in the study were 20, 40, 80 and 
160 µg/ml of blood. Prior to exposing the blood to ozone, the OL80 ozone generator 
(from Ozone Services and Ozone Lab, Burton, BC, Canada) and the needle valve on the 
oxygen cylinder were calibrated for the concentrations used with a low flow rotameter 
and a high flow rotameter (see Appendix A, Table 3a, b and c).  
Appropriate settings were developed from the calibration data to conduct the 
experiment. When using the low flow rotameter, the steel ball was chosen over the glass 
ball because it provided a better fit for the data, R2= 0.975 compared to an R2= 0.94. 
Similarly, when using the high flow rotameter, the steel ball was chosen over the glass 
ball because it provided a better fit for the data, R2= 0.886 compared to an R2= 0.865 (see 
Appendix A, Figure 1a and 1b). 
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The OLC80 ozone generator needed two different oxygen flows to generate the four 
ozone concentrations needed, 31 ml/min and 125 ml/min. Based on the two figures 
mentioned above it was determined that we needed to use the low flow rotameter on a 
setting of 79 for a flow rate of 31 ml/min and the high flow rotameter on a setting of 23 
for a flow rate of 125 ml/min. 
The next step was to calibrate the needle valve on the oxygen cylinder based on 
the rotameter settings. For the low flow rotameter the steel ball and a polynomial function 
provided a better fit for the data.  For the high flow rotameter the steel ball and a 
polynomial function provided a better fit for the data. (see Appendix A, Figure 1c and 
1d). Based on the above mentioned two figures, in order to obtain the flow rates needed 
by the ozone generator, the needle valve had to be positioned on a setting of 8 when using 
the low flow rotameter and a setting of 3.5 when using the high flow rotameter. 
Using ozone-resistant syringes, 2 ml of blood were extracted from the 10 ml 
blood sample into each syringe, resulting in five syringes/blood sample or five 
syringes/patient. The five syringes corresponded to one control and four ozone 
treatments. The ozone generator and needle valve were set for the first ozone 
concentration used and the generator was allowed to run for five minutes to ensure that 
the concentration goal was reached. Then, a 2 ml volume of gas mixture at the desired 
concentration was extracted into the corresponding syringe, previously filled with blood, 
resulting in a 1:1 blood:gas mixture by volume ratio. The syringe was then placed on a 
platform mixer and allowed to mix 20 minutes at low speed to prevent foaming. This 
procedure was repeated for the other ozone concentrations. The control samples received 
2 ml air and were then placed on the platform mixer.  
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 Five blood samples were collected at one time for three out of the four collection 
days. During one of the collection days, one of the patients did not have enough blood to 
donate more than 5 ml of blood, therefore the sample had to be discarded and an 
additional patient enrolled in the study. The total sample size was twenty patients (n=20), 
each donating 10 ml of blood which was further divided into 2 ml subsamples. After the 
blood was divided into amounts specific for the three tests, the empty test tubes were 
disposed of appropriately, no later than 8 hours after blood collection. 
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Erythrocyte sedimentation rate (ESR) 
 
 
After mixing, 1 ml of blood was taken from each syringe and inserted into the 
Wintrobe reservoir of its corresponding graduated tube for ESR. The graduated tube was 
inserted into the reservoir, adjusting its depth so the blood level reaches the “0” mm mark 
on the tube. The tubes had to be placed in a vertical position to prevent any bias in 
determining the sedimentation rate (see figure 2). One hour later, the difference between 
the blood level and the initial “0” mm level was determined. The difference, expressed as 
mm of blood/hour represents the erythrocyte sedimentation rate.  
The erythrocyte sedimentation rates are affected by age and gender. Table 4 
below shows the expected ESR values. 
Table 4. Normal Erythrocyte Sedimentation Rates 
(ESR 95% 
limits) 
mm/hr 
Age (years) 
 20 55 90 
Men 10 14 19 
Women 15 21 23 
 
 All the tubes were discarded following ESR determination. The total number of 
tubes was 100, with five tubes for each of the twenty patients. 
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Figure 2. Wintrobe Tubes for Erythrocyte Sedimentation Rate. 
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C-reactive protein (CRP) 
 
 
The C-reactive protein was assessed according to the Helica Biosystems research 
ELISA (enzyme-linked immunosorbent assay) protocol from blood serum. The serum 
was extracted from the 850 µl of whole blood left available from the 2 ml blood 
subsample. The blood was placed into microcentrifuge tubes and centrifuged to separate 
the serum. The serum was pipetted into fresh centrifuge tubes and frozen at -70ºC for one 
month, until CRP was determined. The total number of CRP samples evaluated was 100, 
which was five samples for each one of the twenty patients. 
The reagents and the five standards were prepared according to the Helica 
protocol. The serum samples underwent a two-step dilution with wash buffer, the first at 
a 1:1,000 ratio and the second at a 1:4 ratio for a 1:4,000 total dilution. One hundred µl 
from each of the diluted serum samples was added in each of the corresponding 
microplate wells. The wells were coated with an affinity purified rabbit antihuman CRP-
IgG. This was the antibody for human serum CRP (antigen). The microplates were then 
incubated at room temperature for 30 minutes to allow the samples to react with the 
antibody coating of the microplate wells. After the incubation, the microplates were 
washed four to five times with buffer (phosphate-buffered saline with Tween 20) and 
placed on paper towels to dry. Each well received 100 µl of conjugate, (a horseradish 
peroxidase (HRP)-labeled rabbit anti-human CRP-IgG with stabilizers and a 
preservative) followed by incubation and buffer washing as above. The purpose of the 
conjugate is to react with and tag the antigen-antibody complexes. After these steps, 100 
µl of TMB (3,3’, 5,5’-tetramethylbenzidine) were added in each well and allowed to 
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incubate for 10 minutes. If a blue color developed, that was an indication of a positive 
sample. Next, 100 µl of Stop solution (phosphoric acid) were added to each well. The 
stop solution causes the color to turn yellow, making it possible to be read in the 
microplate reader at 450 nm. Each microplate was run with a set of standard solutions at 
predetermined concentrations. A standard concentration curve was constructed using the 
absorbancy readings for each of the standards used (Table 5, Figure 3 in Appendix B). 
Table 5. C-Reactive Protein Standards 
Concentration 
(ng/ml) 
Absorbance 
3.33 1.292 
3.33 1.355 
1.11 0.561 
1.11 0.517 
0.37 0.234 
0.37 0.234 
0.12 0.122 
0.12 0.151 
 
 The standard concentration curve was used to convert the absorbancy readings of 
the serum samples into C-reactive protein concentrations, multiplying by four to get the 
actual C-reactive protein serum concentration in µg/ml. The normal C-reactive protein 
levels are those between 0 and 5 µg/ml. However, some researchers consider 10 µg/ml to 
be the upper limit for normal CRP values. In this study, 5 µg/ml was the cut-off value 
used for C-reactive protein because a high risk of heart disease is associated with CRP 
values as low as of 3 µg/ml. 
Higher levels of C-reactive protein are found during late pregnancy, mild 
inflammation and viral infections (10–40 mg/L), active inflammation, bacterial infection 
(40–200 mg/L) and severe bacterial infections and burns (>200 mg/L) (wikipedia.com). 
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Glutathione 
 
 
The remaining 150 µl of blood from the original 2 ml blood sample treated with 
ozone were used to prepare the reduced (GSH) and oxidized (GSSG) glutathione 
samples. There were a total of 100 GSG and 100 GSSG samples, which were ten samples 
for each of the twenty patients.  
Reduced glutathione is a tripeptide that contains a free thiol group. In a 
glutathione peroxidase catalized reaction, two molecules of GSH are bound together to 
form one molecule of GSSH.  
For the accurate measurement of GSSG and the GSH/GSSG ratio, a glutathione 
assay needs to prevent the oxidation of GSH in the sample. In this case, a pyridine 
derivative was used as a thiol-scavenging reagent, which reacts quickly with GSH but 
does not interfere with the activity of the glutathione reductase enzyme. For a GSSG 
sample, thirty µl of thiol scavenger were added to a microcentrifuge tube then 100 µl of 
blood were added to the centrifuge tube and mixed gently. The purpose of the scavenger 
was to keep the glutathione in its oxidized form. For a GSG sample, 50 µl of blood were 
added into an empty centrifuge tube. All the samples were frozen at -70ºC until they were 
used for glutathione determination. 
Prior to glutathione determination, the samples were thawed and prepared 
according to Oxford Biomedical GT-35 protocol as follows. Into the GSSG sample 
centrifuge tube were added 270 µl ice-cold 5% MPA (metaphosphoric acid), making a 
dilution factor x 4 and then the tube was vortexed briefly. The sample was then 
centrifuged at 1000 x g and 4°C for 10 minutes. After centrifuging, 50 µl of the 
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supernatant was collected with a pipette and added to 700 µL assay buffer in a new 
microcentrifuge tube. This step added to a dilution factor x 15 therefore making the total 
dilution factor x 60. The GSH sample centrifuge tube received 350 µL ice-cold 5% MPA, 
a dilution factor x 8 and was vortexed briefly. The sample was then centrifuged at 1000 x 
g and 4°C for 10 minutes. After centrifuging, 25 µl of the supernatant was collected with 
a pipette and added to 1.5 ml assay buffer in a new microcentrifuge tube. This step added 
to a dilution factor x 61 therefore making the total dilution factor x 488. 
In parallel, all the reagents from the assay kit were reconstituted from received 
stock and assay buffer. The seven standard solutions used to make the calibration curve 
for GSG and GSSG were prepared (Table 6). Next, 200 µl of the blank solution (assay 
buffer) was added to a cuvette along with 200 µl DTNB (5,5'-Dithio-Bis 2-Nitrobenzoic 
Acid) solution and 200 µl reductase solution. The solutions in the cuvette were mixed and 
were incubated at room temperature for five minutes. After incubation 200 µl NADPH 
(nicotinamide adenine dinucleotide phosphate) solution added to the cuvette, causing the 
solution to turn yellow. The change of absorbance at 412 nm was recorded by taking 
readings every minute for 10 minutes. This procedure was repeated for all the standards 
and the GSH and GSSG samples.  
Table 6. Glutathione Standards 
Standard µM GSH µM GSSH Rate Net rate 
B0 0.000 0.000 0 0 
S1 0.100 0.050 0.0234 0.0234 
S2 0.250 0.125 0.0293 0.0059 
S3 0.500 0.250 0.0374 0.0315 
S4 1.000 0.500 0.0588 0.0273 
S5 1.500 0.750 0.068 0.0407 
S6 2.000 1.000 0.0708 0.0301 
S7 3.000 1.500 0.1018 0.0717 
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Because the concentration of GSSG is much lower in the reaction mixture 
compared to GSHt the protocol recommends that selected data ranges from the 
calibration curve should be plotted separately. For GSHt, linear regression was done on a 
three-point curve using the 0, 0.50, 0.75, 1.0, and 1.50 µM GSSG (0, 1.0, 1.5, 2.0, and 3.0 
µM GSH) data points. In the case of GSSG, the 0, 0.05, 0.125, and 0.25 µM GSSG data 
points were used (see Appendix C, Figure 4).  
After all the samples were read, an 11-point graph was generated for all samples; 
the slope of the line wass equal to sample rate. The calibration is described by the 
regression equation: 
 
                          Net Rate = Slope x GSH + Intercept 
 
In order to calculate the total GSH (GSHt) or GSSG concentration from the GSH 
calibration curve: 
 
               GSH =((Net Rate – Intercept)/slope) x Dilution Factor 
 
The GSH/GSSG Ratio was calculated using the formula: 
 
                                   Ratio =(GSHt-2xGSSG)/GSSG 
 
 
This assay measured the reduction of GSH to GSSG. The rate of the reaction was 
proportional to the GSH and GSSG concentration. The smaller the GSH/GSSG ratio, the 
higher the oxidative stress, as it would indicate a high amount of oxidized glutathione. 
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Statistical analysis 
 
 
The data was tested for normality using leaf plots, box plots and normal 
probability plots. All three data sets were skewed to the left, indicating smaller numbers 
(smaller erythrocyte sedimentation rates, smaller concentrations of C-reactive protein, 
smaller glutathione ratios) were predominant. 
SAS® statistical package and GLM procedure (General Linear Models) were 
used to detect differences among the ozone treatments and among the samples from the 
patients. The independent variables were the ozone treatments and the patients (samples). 
In the case of ESR, models using additional independent variables –age, gender, age 
nested within gender, interaction between age and gender were also used but only age 
was statistically significant. Least square means were computed for the independent 
variables, with p-values for differences in LS means. 
Any difference with a probability p< 0.05 was considered statistically significant. 
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Results 
 
 
Erythrocyte sedimentation rate 
 
 
An indication of a positive effect of ozone therapies is a decrease in erythrocyte 
sedimentation rate. An increase in the erythrocyte sedimentation rate is a marker of 
inflammatory damage.  
The erythrocyte sedimentation results observed in this study follow the pattern 
shown in previous studies of some positive effects, some negative effects, and some no 
effect. This is further complicated by the fact that some patients may exhibit both positive 
and adverse effects, depending on the ozone concentration used (see results in Table 7 
below). 
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Table 7. Erythrocyte Sedimentation Rate Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
Erythrocyte Sedimentation Rate (mm/hr) 
Concentration * 0 1 2 3 4 
Patient  
A 6 5 7.3 6.5 5 
B 4 9 9 9 7 
C 7 14 12.5 10 7.5 
D 14 14 14 10 15 
E 45 48 42 49 44 
F 39 24 20 40 21 
G 60 18 34 75 57 
H 34 36 32 27 34 
I 4 3 4 4 3 
J 7 8 4 8 8 
K 15 20 12 10 15 
L 29 30 24 25 25 
M 1 16 6 13 52 
N 21 18 25 26 28 
O 10 11 7 7 6 
P 39 40 28 37 27 
Q 48 32 39 29 18 
R 7 8 9 8 9 
S 40 24 18 16 40 
T 1 4 7 4 4 
*Where the ozone concentrations are: 0 =0 µg/ml, 1 =20 µg/ml, 2=40 µg/ml, 3= 80 µg/ml, 
4= 160 µg/ml 
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A decrease in erythrocyte sedimentation rate, a positive effect, was noticed in six 
out of the 20 patients. For the graphical representation see Appendix D, Figures 5c, 5l, 
5o, 5p, 5q and 5s for patients C, L, O, P, Q, and S. The ages of these patients ranged 
between 31 and 73 years old. Out of these six patients, four of them showed a steadily 
decreasing trend in erythrocyte sedimentation rate from the control to the highest ozone 
concentration (Figure 5l, 5o, 5p and 5q). One of the six patients showed a decrease in 
erythrocyte sedimentation rate only for the lowest three ozone concentrations, 20 - 80 
µg/ml (Figure 5s). The last of the six patients showed a decreasing trend in erythrocyte 
sedimentation rate from the lowest ozone concentration, 20 µg/ml to the highest ozone 
concentration 160 µg/ml but all these rates were higher than the baseline, 0 µg ozone/ml 
blood (Figure 5c). 
An increase in erythrocyte sedimentation rate, which is an adverse effect as it 
indicates an inflammatory condition was noticed in four out of the 20 patients. These 
results are shown in Appendix B, Figures 5g, 5m, 5n and 5s for patients G, M, N, and S. 
The ages of these patients ranged from 29 to 63 years old. Two of these four patients 
showed an increasing trend from the control to the highest ozone concentration (Figure 
5m and 5n). One of the four patients showed an increase in the erythrocyte sedimentation 
rate from the lowest ozone concentration to the highest but the results for the two lowest 
ozone concentrations were still better than the patient’s baseline (Figure 5g). The last of 
the four patients showed an increase in erythrocyte sedimentation rate only for the 
highest ozone concentration (Figure 5s). 
A total of eleven patients showed no effect on the erythrocyte sedimentation rate 
when comparing the control and the four ozone concentrations (Figure 5a, 5b, 5d, 5e, 5f, 
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5h, 5i, 5j, 5k, 5r, and 5t for patients A, B, D, E, F, H, I, J, K, R, and T). The ages of these 
patients cover the entire spectrum from 22 to 74 years old. 
When plotting the results for controls only (Figure 6 below), age does not appear 
to have an influence on erythrocyte sedimentation rate. An equal number of people below 
and over 50 years old have normal erythrocyte sedimentation rates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Erythrocyte Sedimentation Rates for Controls. The patients are denoted by 
letters from A to T, arranged based on their age and the number 0 next to the patient 
identification letter represents the baseline, 0 µg ozone/ml blood. 
 
 
Similarly, when plotting the results for the treatments only (Figure 7 below), 
people below and over 50 years old had equal numbers of erythrocyte sedimentation rates 
above the normal limit. 
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Figure 7. Erythrocyte Sedimentation Rates for Ozone Treatments. The patients are 
denoted by letters from A to T, arranged based on their age with the four bars/patient 
representing each ozone concentration in ascending order. 
 
A closer look at the combined effects of ozone and age reveals that people below 
40 years old generally showed a decrease in erythrocyte sedimentation rate with 
increasing ozone concentrations. This is a positive result. In contrast, people above 45 
years old had an increase in erythrocyte sedimentation rate under the four ozone 
concentrations compared to the control. This is an adverse result, indicating an 
inflammatory response (Figure 8a and b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8a. comparison between normal and above normal values 
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Fig. 8b. normal values for men and women 
 
Figure 8. Combined Erythrocyte Sedimentation Rates. 
 
 
Next, the results for the erythrocyte sedimentation rate obtained at the highest 
ozone concentration, C4=160 µg/ml, were compared to the baseline (C0) erythrocyte 
sedimentation rate (Figure 9a). A negative difference between the erythrocyte 
sedimentation rate at the highest ozone concentration and the one at baseline indicates a 
decrease in the erythrocyte sedimentation rate due to ozone treatment, indicating a 
positive result (shown in Figure 9b). Most of the patients who showed a negative C4-C0 
difference were over 60 years old, indicating that they are the category that responds best 
to high ozone concentrations. 
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a.  Values above show a positive (C4-C0) difference, values below show a negative difference 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b.  Nine of the 20 patients showed  a negative C4-C0 difference 
 
 
Figure 9. Difference in Erythrocyte Sedimentation Rate between the Highest Ozone  
Treatment and Baseline 
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old had negative C1-C0 differences indicating a decrease in erythrocyte sedimentation 
rate as a result of ozone treatment (Figure 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Difference in Erythrocyte Sedimentation Rate Between the Lowest Ozone  
Treatment and Baseline 
 
 
However, the statistical models show that there are no statistically significant 
differences among the ozone concentrations, p=0.56. The age of the patients and the 
differences between patients are statistically significant, both with p=0.0001 but for the 
ozone concentrations used the statistical model could not detect a difference among 
ozone treatments. 
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C-reactive protein 
 
 
Similar to the erythrocyte sedimentation rate, an indication of a positive effect of 
ozone therapies is also a decrease in the concentration of C-reactive protein. An increase 
in C-reactive protein is a marker of inflammatory damage.  
Again, the C-reactive protein results observed in this study follow the pattern 
shown in previous studies of some positive effects, some negative effects, and some 
showing no effect. This is further complicated by the fact that some patients may exhibit 
both positive and adverse effects, depending on the ozone concentration (see results in 
Table 8). 
Table 8. C-Reactive Protein Results 
 
 
 
 
 
 
 
 
 
 
 
 
C-reactive protein (mg/l) 
Concentration 0 1 2 3 4 
Patient  
A 0.87 0.51 0.59 0.64 0.66 
B 0.73 0.92 2.23 1.69 3.72 
C 3.14 2.94 4.36 2.16 4.91 
D 0.79 0.48 0.55 0.61 1.34 
E 3.99 1.62 0.98 2.94 0.92 
F 0.56 0.61 0.42 1.25 0.68 
G 2.21 1.72 0.59 1.02 0.66 
H 0.71 1.90 0.79 1.09 0.56 
I 3.86 1.83 0.69 1.71 0.6 
J 0.87 2.64 0.63 1.15 0.83 
K 0.92 0.92 0.66 0.82 0.98 
L 0.77 1.44 1.2 1.11 0.68 
M 12.35 0.93 0.93 4.27 11.45 
N 7.71 6.83 5.03 0.77 0.9 
O 1.26 0.42 0.57 0.44 0.47 
P 0.61 0.72 0.45 0.5 0.49 
Q 1.73 0.56 0.54 0.5 0.56 
R 0.42 0.44 0.41 0.45 0.56 
S 0.99 0.78 0.48 0.58 0.48 
T 0.43 0.44 0.49 0.58 1.09 
Where the ozone concentrations are: 0 =0 µg/ml, 1 =20 µg/ml,  2=40 µg/ml,  3= 80 µg/ml, 4= 160 µg/ml 
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A decrease in C-reactive protein, which is a positive effect, was noticed in five 
out of the 20 patients. For the graphical representation see Appendix E, Figures 11e, 11g, 
11i, 11m, and 10n for patients E, G, I, M, and N. With the exception of patient N the age 
of these five patients ranged between 61 and 64 years old. Out of these five patients, four 
of them showed a steadily decreasing trend in C-reactive protein from the control to the 
highest ozone concentration (Figure 11e, 11g, 11i, and 11n). One of the five patients, 
patient M showed a decrease in C-reactive protein only for the lowest two ozone 
concentrations, 20, respectively 40µg/ml (Figure 11m).  
An increase in C-reactive protein was observed in two out of the 20 patients 
(Figure 11b and previous 11m for patients B and M). The cut-off value used, between 
normal and abnormal C-reactive protein concentrations was of 5 mg/ml. Patient M 
showed previously a decrease in C-reactive protein for the lowest two ozone 
concentrations, with the C-reactive protein increasing for the highest two ozone 
concentrations, 80, respectively 160 µg/ml. This would be interpreted as a negative 
result, however, even with the increase in C-reactive protein these levels were lower than 
the baseline. 
Overall, fourteen out of the 20 patients showed no change in the C-reactive 
protein concentration as a results of ozone treatments. 
 When the results for the 20 patients are combined, it becomes obvious that most 
of the patients had normal C-reactive protein values, except for 3 patients, two of which 
had elevated values only for the highest ozone concentration treatment. The other patient 
had elevated values for the lowest two ozone concentrations (Figure 12). 
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Figure 12. Combined C-Reactive Protein Results 
 
 
The statistical models showed that there are no statistically significant differences 
among the ozone concentrations, p=0.177. Only the differences between patients are 
statistically significant, with p=0.0001. 
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Glutathione 
 
 
An indication of a positive effect of ozone therapies is an increase in the reduced 
to oxidized glutathione ratio. A decrease in the reduced to oxidized glutathione ratio is a 
marker of oxidative stress.  
Similar to erythrocyte sedimentation rate and C-reactive protein, the glutathione 
ratio results observed in this study follow the pattern shown in previous studies of a 
combination of positive, negative effects, and no effects (see Table 9 below). This is 
further complicated by the fact that some patients may exhibit both positive and adverse 
effects, depending on the ozone concentration. 
Table 9. Glutathione Ratio Results 
 
 
 
 
 
 
 
 
 
 
 
 
GSH/GSSG ratio 
Concentration 0 1 2 3 4 
Patient      
A 1.95 1.92 2.47 1.87 2.92 
B 1.97 2.47 1.87 2.09 1.97 
C 2 2.05 2.01 1.99 2.01 
D 2.04 1.96 1.99 1.97 1.95 
E 2.17 1.98 1.3 2.37 1.98 
F 2.04 1.68 1.64 1.7 2.28 
G 2.04 1.68 1.64 1.7 2.28 
H 0.16 1.75 1.97 1.9 4.6 
I 0.99 1.65 1.88 1.86 1.89 
J 1.73 2.05 2.1 2.34 2.75 
K 1.85 1.44 2.4 2.21 3.77 
L 2.01 2.59 1.48 2.21 3.27 
M 1.28 1.6 1.86 1.87 2.13 
N 3.13 2.42 1.72 1.68 1.91 
O 1.37 1.68 1.98 1.21 0.96 
P 1.86 1.82 1.85 1.84 2.08 
Q 1.93 1.34 0.63 1.55 0.81 
R 2.16 1.45 3.51 3.32 2.65 
S 2.5 2.08 2.49 2.22 2.66 
T 2.38 2.68 2.14 2.82 2.83 
Where the ozone concentrations are: 0 =0 µg/ml, 1 =20 µg/ml, 2=40 µg/ml, 3= 80 µg/ml, 4= 160 µg/ml  
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An increase in the glutathione ratio, a positive effect, was noticed in six out of the 
20 patients. For the graphical representation see Appendix F, Figures 13a, 13f, 13h, 13k, 
13l, and 13r for patients A, F, H, K, L, and R. These patients ranged in age from 22 to 74 
years old. One of the six patients, F, experienced an increase in the glutathione ratio only 
for the two highest ozone concentrations, the two lowest ozone concentrations having an 
adverse effect (Figure 13f). 
A decrease in the glutathione ratio, which is an adverse effect, was noticed in four 
out of the 20 patients (Figure 13b, 13f, 13o, and 13q for patients B, F, O, and Q. with 
ages ranging from 22 to 61 years old). Out of these four patients, one showed a decrease 
in the glutathione ratio only for the highest two ozone concentrations (Figure 13o) while 
another showed a decrease in the glutathione ratio only for the lowest two ozone 
concentrations (Figure 13f). 
A total of ten patients showed no effect on the glutathione ratio when comparing 
the control and the four ozone concentrations (Figure 13d, 13e, 13g, 13i, 13j, 13m, 13n, 
13p, 13s, and 3t for patients D, E, G, I, J, M, N, P, S, and T). The ages of these patients 
cover the entire spectrum from 25 to 64 years old. 
The statistical models showed that there are no statistically significant differences 
among the ozone concentrations, p=0.2379 and among the patients, p=0.2495. 
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Combined results 
 
 
The response of the patients to the three tests was combined in Table 10 below. 
The responses were coded with numbers, 0 meaning no effect, positive numbers meaning 
an increase in the parameter tested and negative numbers a decrease in the parameter 
tested.  
 A decrease erythrocyte sedimentation rate or C-reactive protein as a result of 
ozone treatment is a desired positive effect while for glutathione, an increase in the 
GSH/GSSH ratio as a result of ozone treatment is a positive effect. 
 Based on their score for the three tests combined, the patients were assigned into 
categories from I to V with I indicating the highest overall change and V meaning no 
change (see legend below). 
 
Legend: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2 decreasing I    highest change for all 3 tests 
-1 slightly decreasing II  high change across all 3 tests 
0 unchanged III moderate change across all 3 tests 
+1 slightly increasing IV least change across all 3 tests 
+2 increasing V   no change 
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Table 10. Patient Response to all Three Tests 
TEST PATIENT 
 Gender Age ESR CRP 
GSH/GSSG 
ratio Overall change 
A M 74 0 0 +1 IV 
B M 43 0 +2 -1 II 
C M 73 0 +1 n/a IV 
D F 53 0 0 0 V 
E M 63 0 -2 0 III 
F M 22 0 0 0 V 
G M 64 +1 -1 0 III 
H M 45 0 0 +1 IV 
I M 61 0 -2 0 III 
J M 41 0 0 0 V 
K M 60 0 0 0 V 
L M 60 0 0 +2 III 
M M 62 +2 +2* 0 I 
N F 29 +1 -2 0 II 
O M 37 0 0 0 V 
P M 39 -1 0 0 IV 
Q M 61 -2 0 -1 II 
R M 43 0 0 +1 IV 
S F 31 -1 0 0 IV 
T M 25 0 0 +1 IV 
*INCREASE AMONG OZONE CONCENTRATIONS, CONTROL EXCLUDED 
 
 Most patients (12 patients) experienced little to no change to this three tests. Four 
of the patients showed moderate change across all three tests. Three patients showed high 
change across all three tests and only one was extremely responsive to the three tests. The 
patient with the highest responsiveness had the highest increase in erythrocyte 
sedimentation rate compared to the control and C-reactive protein concentration 
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compared to the lowest two ozone concentrations. The patients with high change mostly 
had negative changes as a result of ozone treatment while the patients with moderate 
changes showed positive improvements. 
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Discussion 
 
 
The main purpose of this study was to determine if ozone therapies are harmful 
for the samples and should not be offered as alternative treatment techniques in hospitals. 
Based on the parameters studied, ozone therapies would have a harmful effect if 
the samples experienced a statistically significant increase in erythrocyte sedimentation 
rate and C-reactive protein concentration and a statistically significant decrease in the 
glutathione ratio. Ozone therapies typically use an ozone concentration of 50 µg of 
ozone/ml blood. Ozone bagging techniques utilize concentrations up to 100 µg of 
ozone/ml air mixture. The range of ozone concentrations used in this study were chosen 
to cover the therapeutical spectrum and ranged from 20 µg of ozone/ml blood to160 
µg/ml.  
Our results were not able to reject the primary hypotheses and infer that the ozone 
therapies are harmful. While most of the samples did not have any reaction to the ozone 
treatments, about forty percent of the samples had either a positive or negative response. 
Overall, 30 % of the samples experienced a decrease in erythrocyte sedimentation rate for 
the four ozone concentrations, which is a positive effect of ozone treatments. If the ozone 
concentrations were studied individually, the most efficient ozone concentration was 40 
µg/ml, with 55% of the samples showing a decrease in erythrocyte sedimentation rate. 
When the blood was treated with a concentration of 160 µg/ml, 45% of the samples 
showed a decrease in erythrocyte sedimentation rate. A concentration of 80 µg/ml caused 
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an erythrocyte sedimentation rate decrease in 40 % of the samples while a concentration 
of 20 µg/ml was least efficient, with 35 % of the samples showing a decrease in 
erythrocyte sedimentation rate. If the samples are evaluated individually, 20 % of them 
had the highest decrease in the erythrocyte sedimentation rate at the 80 µg/ml ozone 
concentration, 15 % at 40 µg/ml and 160 µg/ml and 10 % at 20 µg/ml. 
A negative response to the four ozone treatments was found in 20 % of the 
samples. Sixty percent of the samples had a decrease in erythrocyte sedimentation rate at 
20 µg/ml, 55 % of the samples at 80 µg/ml, 40 % at 160 µg/ml and 35 % at 40 µg/ml. 
An overall decrease in the C-reactive protein for each of the four ozone 
concentrations was noticed in 25 % of the samples (changes less than 0.05 mg/l were 
ignored). However, individual ozone concentrations had a bigger impact than their 
combined effect. Most samples showed a positive effect at a particular ozone 
concentration only, while the other concentrations had no effect.  The most efficient 
ozone concentration was again 40 µg/ml, with 75% of the samples showing a decrease in 
C-reactive protein. Concentrations of 160 µg/ml and 80 µg/ml caused a decrease in C-
reactive protein in 65 % of the samples. The lowest ozone concentration, 20 µg/ml 
determined a decrease in C-reactive protein in 55 % of the samples. When the samples 
are evaluated individually, 35 % of them had the highest decrease in C-reactive protein at 
the 40 µg/ml ozone concentration, 20 % at 20 µg/ml and 160 µg/ml and 10 % of the 
samples at 80 µg/ml. 
A negative C-reactive protein response to the four ozone treatments was noticed 
in 10 % of the samples. Each of the two highest ozone concentrations, 80 and 160 µg/ml, 
and the lowest ozone concentration, 20 µg/ml caused a negative response in 30 % of the 
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samples. The 40 µg/ml concentration caused a negative response in 15 % of the samples. 
Individual results showed 30 % of the samples had the highest negative response at the 
highest ozone concentration, 160 µg/ml, 20 % of the samples at the lowest ozone 
concentration, 0.2 µg/ml and 10 % at the 80 µg/ml concentration. 
For the glutathione ratio, a positive effect was represented by an increase in the 
ratio as a result of exposure to ozone (changes less than 0.1 were ignored). Thirty % of 
the samples had a positive response for all ozone concentrations. Some samples 
responded to only one particular ozone concentration. The highest ozone concentration, 
160 µg/ml proved to be the most effective with 65 % of the samples experiencing an 
increase in the glutathione ratio. This was followed by the 80 µg/ml concentration with 
50 % of the samples and the lowest ozone concentrations each with 40 % of the samples. 
When the samples are evaluated individually, 60 % of them had the highest increase in 
the glutathione ratio at the 160 µg/ml ozone concentration, 10 % at 20 µg/ml and 40 
µg/ml and 5 % of the samples at 80 µg/ml. 
A negative glutathione ratio response to the four ozone treatments was noticed in 
20 % of the samples. Each of the two lowest ozone concentrations, 20 and 40 µg/ml, 
caused a negative response in 40 % of the samples, followed by the 80 µg/ml 
concentration with 30 % of the samples and 160 µg/ml with 20 % of the samples. When 
the samples are evaluated individually, 10 % of them had the highest increase in the 
glutathione ratio at the 160 µg/ml ozone concentration, respectively 80 µg/ml, 25 % at 20 
µg/ml and 35 % of the samples at 40 µg/ml. 
Most of the samples showed none to little response to ozone treatments for the 
three tests studied, as it was reinforced by the lack of statistical significance when the 
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differences between treatments were evaluated. The statistical models as a whole, which 
included the samples as the independent variable and their age and gender (for 
erythrocyte sedimentation rate) were statistically significant. However the results for the 
three tests were not able to determine a difference between the ozone concentrations 
used. This means that the study could not prove that ozone therapies are harmful, even 
though some of the concentrations used were significantly higher than the therapeutical 
concentrations.   
However, most of the samples (12) showed an improvement in one of the tests. 
This suggests that ozone therapies can be used to improve the general health status of a 
patient. Even though the ozone therapies may not have the potency to cure cancer or 
AIDS, they could be a very useful tool if they are used as an adjuvant for established 
medical procedures if their effect is additive. The results obtained in this study 
demonstrate the difficulty that previous studies had in pinpointing an effect of ozone 
therapies. It appears clear that the ozone therapies have to be tailored for the individual as 
there is no general formula for their effectiveness. It is also possible that the blood may 
not be an appropriate media for testing the effect of ozone therapies as the blood 
antioxidant capacity may be able to counteract some of these effects. 
For future research, it would be very useful to develop a better test, using 
parameters that correlate with ozone therapy concentrations, with a greater sensitivity and 
lower variability for the data. 
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Appendix A (Continued) 
 
Table 3. Calibration Data for the Rotameters and Needle Valve 
a. Low Flow (0-0.05 l/min) Rotameter 
 
CALIBRATION OF LOW FLOW ROTAMETER- GLASS BALL 
SETTING VOLUME TIME TIME FLOW RATE SETTING FLOW RATE 
 CC SECONDS MINUTES CC/MIN  ML/MIN 
51 5 57 0.95 5.3 46 5.3 
46 5 59 0.98 5.1 51 5.3 
101 5 24 0.40 12.5 94 12.5 
98 5 25 0.42 12.0 96 12.0 
96 5 27 0.45 11.1 98 11.1 
94 5 27 0.45 11.1 101 11.1 
117 5 19 0.32 15.8 111 15.8 
115 5 21 0.35 14.3 113 14.3 
113 5 20 0.33 15.0 115 15.0 
111 5 21 0.35 14.3 117 14.3 
140 5 14 0.23 21.4 138 21.4 
139 5 15 0.25 20.0 139 20.0 
138 5 15 0.25 20.0 140 20.0 
 
CALIBRATION OF LOW FLOW ROTAMETER- STAINLESS STEEL BALL 
SETTING VOLUME TIME TIME FLOW RATE SETTING FLOW RATE 
 CC SECONDS MINUTES CC/MIN  ML/MIN 
14 5 57 0.95 5.3 12 5.26 
12 5 59 0.98 5.1 14 5.08 
38 5 24 0.40 12.5 34 12.50 
36 5 25 0.42 12.0 35 12.00 
35 5 27 0.45 11.1 36 11.11 
34 5 27 0.45 11.1 38 11.11 
47 5 19 0.32 15.8 44 15.79 
46 5 21 0.35 14.3 45 14.29 
45 5 20 0.33 15.0 46 15.00 
44 5 21 0.35 14.3 47 14.29 
68 5 14 0.23 21.4 62 21.43 
66 5 15 0.25 20.0 66 20.00 
62 5 14 0.23 21.4 68 21.43 
110 5 7 0.12 42.9 105 42.86 
109 5 8 0.13 37.5 108 37.50 
108 5 7 0.12 42.9 109 42.86 
105 5 7 0.12 42.9 110 42.86 
136 5 5 0.08 60.0 135 60.00 
136 5 5 0.08 60.0 136 60.00 
136 5 5 0.08 60.0 136 60.00 
135 5 5 0.08 60.0 136 60.00 
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Appendix A (Continued) 
 
Table 3 (Continued) 
b. High Flow (0.05-0.8 l/min) Rotameter 
 
CALIBRATION OF HIGH FLOW ROTAMETER 
GLASS BALL 
SETTING VOLUME TIME TIME FLOW RATE SETTING FLOW RATE 
 CC SECONDS MINUTES CC/MIN  ML/MIN 
27 5 6 0.10 50.0 27 50.00 
27 5 6 0.10 50.0 27 50.00 
27 5 6 0.10 50.0 27 50.00 
27 5 7 0.12 42.9 27 42.86 
27 5 7 0.12 42.9 27 42.86 
27 5 7 0.12 42.9 27 42.86 
40 5 7 0.12 42.9 39 42.86 
40 5 4 0.07 75.0 39 75.00 
40 5 5 0.08 60.0 39 60.00 
39 5 5 0.08 60.0 39 60.00 
39 5 5 0.08 60.0 40 60.00 
39 5 4 0.07 75.0 40 75.00 
39 5 5 0.08 60.0 40 60.00 
60 5 5 0.08 60.0 60 60.00 
60 5 3 0.05 100.0 60 100.00 
60 5 3 0.05 100.0 60 100.00 
60 5 3 0.05 100.0 60 100.00 
60 5 3 0.05 100.0 60 100.00 
60 5 3 0.05 100.0 60 100.00 
97 5 3 0.05 100.0 97 100.00 
97 5 2 0.03 150.0 97 150.00 
97 5 2 0.03 150.0 97 150.00 
97 40 11 0.18 218.2 97 218.18 
97 40 11 0.18 218.2 97 218.18 
146 30 5 0.08 360.0 146 360.00 
146 40 6 0.10 400.0 146 400.00 
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Appendix A (Continued) 
 
Table 3b. (Continued)  
 
CALIBRATION OF HIGH FLOW ROTAMETER 
STAINLESS STEEL BALL 
SETTING VOLUME TIME TIME FLOW RATE SETTING FLOW RATE 
 CC SECONDS MINUTES CC/MIN  ML/MIN 
2 5 6 0.10 50 2 50.00 
2 5 6 0.10 50 2 50.00 
2 5 6 0.10 50 2 50.00 
2 5 7 0.12 43 2 42.86 
2 5 7 0.12 43 2 42.86 
2 5 7 0.12 43 2 42.86 
2 5 7 0.12 43 2 42.86 
10 5 5 0.08 60 10 60.00 
10 5 5 0.08 60 10 60.00 
10 5 4 0.07 75 10 75.00 
10 5 5 0.08 60 10 60.00 
10 5 4 0.07 75 10 75.00 
10 5 5 0.08 60 10 60.00 
10 5 5 0.08 60 10 60.00 
24 5 3 0.05 100 24 100.00 
24 5 3 0.05 100 24 100.00 
24 5 3 0.05 100 24 100.00 
24 5 3 0.05 100 24 100.00 
24 5 3 0.05 100 24 100.00 
24 5 3 0.05 100 24 100.00 
44 5 2 0.03 150 44 150.00 
44 5 2 0.03 150 44 150.00 
44 5 1 0.02 300 44 300.00 
44 40 11 0.18 218 44 218.18 
44 40 11 0.18 218 44 218.18 
69 30 5 0.08 360 69 360.00 
69 40 6 0.10 400 69 400.00 
 
 
 
 
 
 
 
 
 
 
 
 59 
Appendix A (Continued) 
 
Table 3 (Continued) 
c. Calibration of the Needle Valve for the Low Flow and High Flow Rotameters 
 
Low flow rotameter High flow rotameter 
  Setting   Setting 
Needle valve Glass  Steel  Needle valve Glass  Steel  
setting ball ball setting ball ball 
6.5 0.0 5 2 0 8 
6.5 0.0 6 2 0 11 
6.5 0.0 6 2 0 11 
6.5 0.0 6 4 0 25 
7 0.0 9 4 0 25 
7 0.0 10 4 0 26 
7 0.0 10 6 11 41 
7 0.0 10 6 11 41 
7.5 0.0 11 6 11 41 
7.5 0.0 11 8 29 69 
7.5 0.0 12 8 29 69 
7.5 0.0 12 8 29 69 
8 18.0 73 10 33 84 
8 30.0 74 10 37 86 
8 21.0 80 10 36 86 
8 24.0 85       
8.5 71.0 140       
8.5 73.0 143       
8.5 74.0 143       
8.5 66.0 150       
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a. Calibration of the low flow (0-0.05 l/min) rotameter using the steel ball. 
 
 
 
 
 
 
 
b. Calibration of the high flow (0.05-0.8 l/min) rotameter using the steel ball. 
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c. Calibration of the needle valve for the low flow rotameter. 
 
 
 
 
 
 
 
 
d. Calibration of the needle valve for the high flow rotameter. 
 
Figure 1. Calibration Data for the Rotameters and Needle Valve 
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Figure 3. Calibration Curve for C-Reactive Protein 
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Figure 4. Calibration Curves for Glutathione
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Figure 5. Erythrocyte Sedimentation Rates 
 
Note: In the following figures, the capital letter denotes the patient (from A to T), the 0-4 
numbers represent the ozone concentration (4 being the highest ozone concentration), the 
small letter ‘s’ denotes a GSH sample and the double letter ‘ss’ denotes a GSSG sample. 
The green line indicates a positive effect and the red line an adverse effect. 
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Figure 11. C-Reactive Protein Results 
 
Note: In the following figures, the capital letter denotes the patient (from A to T), the 0-4 
numbers represent the ozone concentration (4 being the highest ozone concentration). 
Green lines represent a positive effect, red lines an adverse effect. 
 
 
For example: B2 means sample from patient B, 2nd highest ozone concentration treatment
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Figure 13. Glutathione Absorbancies for Ozone Treatments 
 
Note: In the following figures, the capital letter denotes the patient (from A to T), the 0-4 
numbers represent the ozone concentration (4 being the highest ozone concentration), the 
small letter ‘s’ denotes a GSH sample and the double letter ‘ss’ denotes a GSSG sample. 
 
For example: A2s means patient A, 2nd highest ozone concentration treatment, GSH 
sample. 
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Appendix F (Continued) 
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